Literature DB >> 21655823

Epidemiology of fungal infections in liver transplant recipients: a six-year study of a large Brazilian liver transplantation centre.

Michelle Zicker1, Arnaldo Lopes Colombo, Ben-Hur Ferraz-Neto, Luis Fernando Aranha Camargo.   

Abstract

Liver transplant seems to be an effective option to prolong survival in patients with end-stage liver disease, although it still can be followed by serious complications. Invasive fungal infections (ifi) are related to high rates of morbidity and mortality. The epidemiology of fungal infections in Brazilian liver transplant recipients is unknown. The aim of this observational and retrospective study was to determine the incidence and epidemiology of fungal infections in all patients who underwent liver transplantation at Albert Einstein Israeli Hospital between 2002-2007. A total of 596 liver transplants were performed in 540 patients. Overall, 77 fungal infections occurred in 68 (13%) patients. Among the 77 fungal infections, there were 40 IFI that occurred in 37 patients (7%). Candida and Aspergillus species were the most common etiologic agents. Candida species accounted for 82% of all fungal infections and for 67% of all IFI, while Aspergillus species accounted for 9% of all fungal infections and for 17% of all IFI. Non-albicans Candida species were the predominant Candida isolates. Invasive aspergillosis tended to occur earlier in the post-transplant period. These findings can contribute to improve antifungal prophylaxis and therapy practices in Brazilian centres.

Entities:  

Mesh:

Year:  2011        PMID: 21655823     DOI: 10.1590/s0074-02762011000300014

Source DB:  PubMed          Journal:  Mem Inst Oswaldo Cruz        ISSN: 0074-0276            Impact factor:   2.743


  8 in total

1.  Observational Study of Associations between Voriconazole Therapeutic Drug Monitoring, Toxicity, and Outcome in Liver Transplant Patients.

Authors:  Zahra Hashemizadeh; Parisa Badiee; Seyed Ali Malekhoseini; Hadi Raeisi Shahraki; Bita Geramizadeh; Hashem Montaseri
Journal:  Antimicrob Agents Chemother       Date:  2017-11-22       Impact factor: 5.191

Review 2.  Approach to the Solid Organ Transplant Patient with Suspected Fungal Infection.

Authors:  Judith A Anesi; John W Baddley
Journal:  Infect Dis Clin North Am       Date:  2015-12-28       Impact factor: 5.982

3.  Analysis of infections in the first 3-month after living donor liver transplantation.

Authors:  Chuan Li; Tian-Fu Wen; Kai Mi; Chuan Wang; Lu-Nan Yan; Bo Li
Journal:  World J Gastroenterol       Date:  2012-04-28       Impact factor: 5.742

4.  Cutaneous infection by different Alternaria species in a liver transplant recipient.

Authors:  Susana Brás; Raquel Sabino; André Laureano; Helena Simões; Cândida Fernandes; Gabriela Marques-Pinto; Jorge Cardoso; Cristina Veríssimo
Journal:  Med Mycol Case Rep       Date:  2015-01-29

5.  Randomized trial of micafungin for the prevention of invasive fungal infection in high-risk liver transplant recipients.

Authors:  Faouzi Saliba; Andreas Pascher; Olivier Cointault; Pierre-François Laterre; Carlos Cervera; Jan J De Waele; Umberto Cillo; Róbert M Langer; Manuela Lugano; Bo Göran-Ericzon; Stephen Phillips; Lorraine Tweddle; Andreas Karas; Malcolm Brown; Lutz Fischer
Journal:  Clin Infect Dis       Date:  2014-12-17       Impact factor: 9.079

6.  Risk factors for invasive pulmonary aspergillosis and hospital mortality in acute-on-chronic liver failure patients: a retrospective-cohort study.

Authors:  Jiajia Chen; Qing Yang; Jianrong Huang; Lanjuan Li
Journal:  Int J Med Sci       Date:  2013-09-18       Impact factor: 3.738

7.  Clinical findings in 19 cases of invasive pulmonary aspergillosis with liver cirrhosis.

Authors:  Jiajia Chen; Qing Yang; Jianrong Huang; Lanjuan Li
Journal:  Multidiscip Respir Med       Date:  2014-01-08

Review 8.  Echinocandins for management of invasive candidiasis in patients with liver disease and liver transplantation.

Authors:  Siang Fei Yeoh; Tae Jin Lee; Ka Lip Chew; Stephen Lin; Dennis Yeo; Sajita Setia
Journal:  Infect Drug Resist       Date:  2018-05-30       Impact factor: 4.003

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.